Cadila Pharmaceuticals Ltd., the privately-owned Indian player, says it has expanded its oncology portfolio by introducing a biosimilar to Avastin (bevacizumab) in its local market.
Named Bevaro, the biosimilar will be made available in a single dose vial of two strengths, 100mg and 400mg.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?